Tearsheet
TFX Home Investment Highlights Valuation, Metrics & Events Price Chart Why The Stock Moved Return vs. Risk About TFX Interactive Breakdown Better Bets vs. TFX Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Trade Sentinel Industry Resource Links External Quote Links

Teleflex (TFX)

Market Price (2/16/2026): $103.77 | Market Cap: $4.6 Bil
Sector: Health Care | Industry: Health Care Equipment

Teleflex (TFX)

Market Price (2/16/2026): $103.77
Market Cap: $4.6 Bil
Sector: Health Care
Industry: Health Care Equipment

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%		 Weak multi-year price returns
2Y Excs Rtn is -94%, 3Y Excs Rtn is -124%		 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 53%
1 Attractive yield
FCF Yield is 5.8%		  Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%
2 Low stock price volatility
Vol 12M is 43%		  Key risks
TFX key risks include [1] heightened operational and execution challenges from the simultaneous acquisition of BIOTRONIK's vascular business and the planned spin-off of three other divisions, Show more.
3 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Medical Device Innovation. Themes include Geriatric Care, Minimally Invasive Surgical Solutions, Show more.		  
0 Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 12%
1 Attractive yield
FCF Yield is 5.8%
2 Low stock price volatility
Vol 12M is 43%
3 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease, and Medical Device Innovation. Themes include Geriatric Care, Minimally Invasive Surgical Solutions, Show more.
4 Weak multi-year price returns
2Y Excs Rtn is -94%, 3Y Excs Rtn is -124%
5 Debt is significant
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 53%
6 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -11%
7 Key risks
TFX key risks include [1] heightened operational and execution challenges from the simultaneous acquisition of BIOTRONIK's vascular business and the planned spin-off of three other divisions, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Teleflex (TFX) stock has lost about 15% since 10/31/2025 because of the following key factors:

1. Reduced 2025 Revenue Outlook and Leadership Transition

Teleflex significantly cut its preliminary 2025 revenue outlook to approximately $3.27 billion to $3.28 billion, primarily attributing this reduction to softer demand for intra-aortic balloon pumps and catheters, as well as delays in OEM purchase orders and lower volumes in some segments. This guidance revision, coupled with the immediate departure of long-standing CEO Liam Kelly and the appointment of an interim CEO, Stuart Randle, created substantial investor uncertainty during this period.

2. Underperforming Key Segments and Missed Growth Targets

The company reported organic revenue growth of 2.1%, which fell short of the expected 2.7%, indicating difficulties in meeting growth forecasts. Declines in critical segments, particularly Interventional and Interventional Urology, and concerns surrounding integration and divestiture risks, further contributed to a cautious outlook. Management highlighted missed order rates for intra-aortic balloon pumps due to extended replacement cycles in hospitals, and prior weak demand in Interventional Urology had already impacted other units, leading to a subdued 2025 revenue guidance implying minimal to no growth.

Show more

Stock Movement Drivers

Fundamental Drivers

The -16.4% change in TFX stock from 10/31/2025 to 2/15/2026 was primarily driven by a -20.3% change in the company's P/S Multiple.
(LTM values as of)103120252152026Change
Stock Price ($)124.08103.75-16.4%
Change Contribution By: 
Total Revenues ($ Mil)3,0413,1904.9%
P/S Multiple1.81.4-20.3%
Shares Outstanding (Mil)44440.1%
Cumulative Contribution-16.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 2/15/2026
ReturnCorrelation
TFX-16.4% 
Market (SPY)-0.0%26.9%
Sector (XLV)9.3%25.7%

Fundamental Drivers

The -12.7% change in TFX stock from 7/31/2025 to 2/15/2026 was primarily driven by a -16.8% change in the company's P/S Multiple.
(LTM values as of)73120252152026Change
Stock Price ($)118.80103.75-12.7%
Change Contribution By: 
Total Revenues ($ Mil)3,0413,1904.9%
P/S Multiple1.71.4-16.8%
Shares Outstanding (Mil)44440.1%
Cumulative Contribution-12.7%

LTM = Last Twelve Months as of date shown

Market Drivers

7/31/2025 to 2/15/2026
ReturnCorrelation
TFX-12.7% 
Market (SPY)8.2%31.2%
Sector (XLV)21.4%36.0%

Fundamental Drivers

The -41.8% change in TFX stock from 1/31/2025 to 2/15/2026 was primarily driven by a -47.7% change in the company's P/S Multiple.
(LTM values as of)13120252152026Change
Stock Price ($)178.26103.75-41.8%
Change Contribution By: 
Total Revenues ($ Mil)3,0263,1905.4%
P/S Multiple2.81.4-47.7%
Shares Outstanding (Mil)47445.6%
Cumulative Contribution-41.8%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2025 to 2/15/2026
ReturnCorrelation
TFX-41.8% 
Market (SPY)14.3%35.7%
Sector (XLV)8.8%40.3%

Fundamental Drivers

The -56.4% change in TFX stock from 1/31/2023 to 2/15/2026 was primarily driven by a -63.9% change in the company's P/S Multiple.
(LTM values as of)13120232152026Change
Stock Price ($)237.78103.75-56.4%
Change Contribution By: 
Total Revenues ($ Mil)2,7953,19014.1%
P/S Multiple4.01.4-63.9%
Shares Outstanding (Mil)47446.0%
Cumulative Contribution-56.4%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2023 to 2/15/2026
ReturnCorrelation
TFX-56.4% 
Market (SPY)74.0%36.6%
Sector (XLV)23.7%43.6%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
TFX Return-20%-24%0%-28%-31%-14%-74%
Peers Return12%-12%12%14%6%-6%25%
S&P 500 Return27%-19%24%23%16%-0%82%

Monthly Win Rates [3]
TFX Win Rate33%50%50%50%50%50% 
Peers Win Rate55%48%55%62%57%30% 
S&P 500 Win Rate75%42%67%75%67%50% 

Max Drawdowns [4]
TFX Max Drawdown-29%-43%-28%-30%-41%-18% 
Peers Max Drawdown-9%-26%-8%-8%-8%-9% 
S&P 500 Max Drawdown-1%-25%-1%-2%-15%-1% 

[1] Cumulative total returns since the beginning of 2021
[2] Peers: MDT, BDX, BSX, EW, SYK. See TFX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)

How Low Can It Go

Unique KeyEventTFXS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-59.6%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven147.4%34.1%
2022 Inflation ShockTime to BreakevenTime to BreakevenNot Fully Recovered days464 days
2020 Covid Pandemic2020 Covid Pandemic  
2020 Covid Pandemic% Loss% Loss-43.0%-33.9%
2020 Covid Pandemic% Gain to Breakeven% Gain to Breakeven75.4%51.3%
2020 Covid PandemicTime to BreakevenTime to Breakeven128 days148 days
2018 Correction2018 Correction  
2018 Correction% Loss% Loss-20.7%-19.8%
2018 Correction% Gain to Breakeven% Gain to Breakeven26.1%24.7%
2018 CorrectionTime to BreakevenTime to Breakeven199 days120 days
2008 Global Financial Crisis2008 Global Financial Crisis  
2008 Global Financial Crisis% Loss% Loss-55.7%-56.8%
2008 Global Financial Crisis% Gain to Breakeven% Gain to Breakeven125.9%131.3%
2008 Global Financial CrisisTime to BreakevenTime to Breakeven1,463 days1,480 days

Compare to MDT, BDX, BSX, EW, SYK

In The Past

Teleflex's stock fell -59.6% during the 2022 Inflation Shock from a high on 4/28/2021. A -59.6% loss requires a 147.4% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Teleflex (TFX)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. The company also offers interventional products, which consists of various coronary catheters, structural heart therapies, and peripheral intervention and cardiac assist products that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded catheters, Guideline and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. It provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. The company also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; and respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings. It provides urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. The company was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

AI Analysis | Feedback

Medtronic for essential hospital medical devices.

A specialized Johnson & Johnson for hospital medical supplies.

Stryker for a broader range of critical care and surgical devices.

AI Analysis | Feedback

```html
  • Vascular Access Products: A comprehensive portfolio of catheters, guide wires, and related devices used for delivering fluids and monitoring patients.
  • Anesthesia Products: Airway management devices, including laryngeal mask airways (LMAs) and endotracheal tubes, along with regional anesthesia solutions.
  • Surgical Products: Surgical instruments, ligation systems, and fascial closure devices for various open and minimally invasive surgical procedures.
  • Urology Products: Catheters and related devices for bladder management and other urological care applications.
  • Interventional Products: Specialized guide wires, catheters, and access devices primarily used in interventional cardiology and radiology procedures.
  • Original Equipment Manufacturer (OEM) Components: Custom extrusion and precision components provided to other medical device manufacturers.
```

AI Analysis | Feedback

Teleflex (TFX) - Major Customers

Teleflex (TFX) sells primarily to other companies and healthcare organizations, rather than directly to individuals. As a global provider of medical devices, its customer base is highly fragmented across thousands of healthcare facilities and purchasing organizations worldwide. Therefore, it does not typically disclose a few specific "major customers" by name and stock symbol in the way a component supplier might name a finished goods manufacturer.

However, the categories of major customers for Teleflex include:

  • Hospitals and Acute Care Facilities: These are the primary end-users of Teleflex's surgical, critical care, vascular access, and anesthesia products. This includes general hospitals, specialized hospitals, and university medical centers globally.
  • Ambulatory Surgery Centers (ASCs) and Clinics: As healthcare delivery shifts towards outpatient settings, ASCs and various specialized clinics represent a growing customer segment for many of Teleflex's less invasive products and supplies.
  • Integrated Delivery Networks (IDNs): In the United States, IDNs are large healthcare systems that own and operate multiple hospitals, clinics, and other healthcare facilities. They often make purchasing decisions centrally, making them significant customers.
  • Group Purchasing Organizations (GPOs): While not direct end-users, GPOs are crucial intermediaries, particularly in the U.S. They negotiate contracts for medical products and services on behalf of their member hospitals, IDNs, and other healthcare providers. Teleflex works closely with major GPOs to gain access to their extensive member networks.
  • Governmental Healthcare Providers: This includes national health services (e.g., NHS in the UK), Veterans Affairs (VA) hospitals in the U.S., and other public healthcare systems around the world.

Due to the nature of the medical device industry, these customers are typically private organizations, government entities, or large healthcare systems that are not publicly traded as individual entities for the purpose of identifying "customer symbols."

AI Analysis | Feedback

null

AI Analysis | Feedback

Liam J. Kelly, Chairman, President and Chief Executive Officer

Mr. Kelly became Chairman of the Teleflex Board on May 1, 2020, and has served as the company's President and Chief Executive Officer since January 1, 2018. He joined Teleflex in April 2009 and held various executive leadership roles, including President of EMEA, Executive Vice President and President, International, Executive Vice President and President, Americas, and Executive Vice President and Chief Operating Officer. Prior to joining Teleflex, Mr. Kelly held senior leadership positions at Hill-Rom Holdings, Inc., a medical device company, from 2002 to 2009, where he served as Vice President of International Marketing and Product Development and as Managing Director of their UK & Ireland businesses.

John R. Deren, Executive Vice President and Chief Financial Officer

Mr. Deren has been the Executive Vice President and Chief Financial Officer of Teleflex since April 2, 2025. He previously served as the Chief Accounting Officer and Vice President of the company. Before Teleflex, Mr. Deren was the Vice President and Global Controller at Trinseo. Earlier in his career, he served as the Assistant Controller of Exelon Generation and of Rohm and Haas Co.

Jay K. White, Corporate Vice President and President, Global Commercial

Mr. White serves as Corporate Vice President and President, Global Commercial at Teleflex.

Daniel V. Logue, Corporate Vice President, General Counsel and Secretary

Mr. Logue holds the position of Corporate Vice President, General Counsel and Secretary at Teleflex.

James P. Winters, Corporate Vice President, Manufacturing and Supply Chain

Mr. Winters is the Corporate Vice President, Manufacturing and Supply Chain for Teleflex.

AI Analysis | Feedback

The key risks to Teleflex (TFX) are primarily centered around its significant strategic restructuring, substantial indebtedness, and the complexities of regulatory compliance within the medical device industry. These risks are presented in order from most significant to less significant.

  1. Execution and Integration Risks from Strategic Transactions: Teleflex is undertaking significant strategic initiatives, including the acquisition of BIOTRONIK's Vascular Intervention business and the planned spin-off of its Acute Care, OEM, and Urology businesses. The integration of the BIOTRONIK acquisition carries risks such as not achieving intended growth, revenue, and operating income targets, as well as incurring unexpected costs or experiencing delays. Simultaneously, the proposed business separation introduces considerable execution and operational risks. These include the potential for increased volatility and costs, challenges in securing regulatory approvals, and the risk that the resulting independent companies may be smaller and less diversified, making them more vulnerable to market fluctuations. Moody's revised Teleflex's outlook to negative, citing heightened operational and execution risks due to these combined transactions, which are expected to reduce Teleflex's scale and business diversity.

  2. Substantial Indebtedness and Financial Flexibility: Teleflex carries a significant amount of consolidated indebtedness, reported at approximately $1.7 billion as of December 31, 2024. This substantial debt level poses a risk to the company's financial condition and results of operations, as it may hinder its ability to generate sufficient cash flow to meet its debt obligations. Recent strategic financing for acquisitions and share repurchases has further contributed to this debt load, potentially limiting the company's financial flexibility and increasing its vulnerability to adverse economic conditions or changes in interest rates.

  3. Regulatory Challenges and Compliance Costs: As a global provider of medical technology products, Teleflex operates in a highly regulated environment and is subject to extensive government regulations both in the U.S. and internationally. Compliance with these regulations is costly and time-consuming. Changes in regulatory frameworks, such as the EU Medical Device Regulation (MDR) and new environmental standards (e.g., EPA standards for ethylene oxide emissions), could significantly impact operations. The MDR, in particular, requires the re-registration of many previously approved medical devices, leading to additional expenditures for the company.

AI Analysis | Feedback

null

AI Analysis | Feedback

Teleflex (symbol: TFX) operates in various medical technology segments, with addressable markets as follows:

  • Vascular Access: The global vascular access device market was valued at approximately USD 5.78 billion in 2023 and is projected to reach USD 9.40 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.2%. Another estimate values the market at USD 5.99 billion in 2024, expected to reach USD 9.05 billion by 2030, with a CAGR of 7.1%. North America is anticipated to hold a major share of this market.
  • Anesthesia and Respiratory Devices: The global market for anesthesia and respiratory devices was estimated at USD 56.3 billion in 2024 and is expected to grow to USD 91.5 billion by 2033, with a CAGR of 5.6% from 2025 to 2033. More specifically for anesthesia devices, the global market size was estimated at USD 17.45 billion in 2024 and is projected to reach USD 42.80 billion by 2035, growing at a CAGR of 8.50% from 2025 to 2035. The U.S. anesthesia devices market was estimated at USD 6.49 billion in 2024 and is projected to reach approximately USD 13.25 billion by 2034. North America held the largest revenue share in the anesthesia and respiratory devices market in 2024.
  • Interventional Cardiology and Peripheral Vascular: Teleflex is committed to investing in the estimated USD 10 billion global interventional cardiology and peripheral vascular market. The global interventional cardiology devices market size was estimated at USD 10.57 billion in 2024 and is projected to reach USD 19.75 billion by 2033, growing at a CAGR of 7.25% from 2025 to 2033. Another report indicates the global interventional cardiology devices market size was USD 16.69 billion in 2024, projected to grow to USD 29.32 billion by 2032 with a CAGR of 7.3% from 2025. North America dominated the interventional cardiology devices market in 2024 with a 45.06% revenue share.
  • Interventional Urology (within Urology Devices): The global urology devices market was estimated at USD 36.8 billion in 2024 and is expected to grow from USD 39.3 billion in 2025 to USD 73.5 billion in 2034, at a CAGR of 7.2%. Another source indicates the global urology devices market size was USD 36.34 billion in 2024, with a projection to reach USD 64.33 billion by 2032, exhibiting a CAGR of 7.4%. North America held the largest market share in the global urology devices market in 2024 at 42.5%. The U.S. urology surgical instruments market alone is expected to reach US$6,497.7 million by 2030, growing at a CAGR of 7.5% from 2025 to 2030. Teleflex's Interventional Urology segment includes products like the UroLift System and Barrigel.
  • Surgical: The global surgical retractors market size, a specific area within surgical products, is expected to reach USD 1.81 billion by 2025.
  • Cardiac Assist Devices: The global cardiac assist devices market was valued at USD 2.89 billion in 2023 and is projected to reach USD 6.23 billion by 2030, growing at a CAGR of 13.70% from 2024 to 2030. Another forecast estimates an 8.0% CAGR for the market from 2023 to 2031. North America is predicted to experience the fastest growth in this market.

For the product areas of Emergency Medicine and OEM (Original Equipment Manufacturing), specific addressable market sizes for Teleflex's offerings were not readily available in the search results. Therefore, the market size for these categories is null.

AI Analysis | Feedback

Teleflex (TFX) is expected to drive future revenue growth over the next two to three years through several key strategies and product line expansions:

  1. Strategic Acquisitions and Integration: The acquisition and integration of the Vascular Intervention business, particularly the former BIOTRONIK assets, is a significant driver. This acquisition is expected to contribute substantially to revenue, with management anticipating the combined Interventional business to generate over $800 million in annual revenues. The acquired portfolio alone was projected to bring in $204 million in the second half of 2025.
  2. Growth in the Interventional Segment: Beyond the recent acquisitions, Teleflex anticipates continued strong performance from its broader Interventional segment. Key products like intra-aortic balloon pumps (IABP), OnControl, and complex catheters have been identified as strong contributors to this segment's growth, even as the company monitors order rates for IABPs.
  3. Expansion of the Global Vascular Access Portfolio: The company's Vascular Access segment, which includes products such as peripheral access, EZ-IO, and central access products, is consistently cited as a strong performer and a driver of revenue increases.
  4. Increased Adoption and Geographic Expansion of Barrigel: Following the acquisition of Palette Life Sciences, Barrigel revenue has been a notable growth driver within Interventional Urology. Teleflex's strategy includes expanding the usage and geographic availability of Barrigel products to further contribute to revenue growth.

AI Analysis | Feedback

Capital Allocation Decisions (Last 3-5 Years)

Share Repurchases

  • In August 2024, Teleflex's Board of Directors authorized a share repurchase program of up to $500 million, which included a $200 million accelerated share repurchase (ASR).
  • As part of this authorization, the company initiated a $300 million ASR in March 2025, which was completed on April 9, 2025.

Share Issuance

  • Teleflex's shares outstanding have shown a declining trend, with 0.044 billion shares outstanding as of June 30, 2025, a 6.4% decline year-over-year.
  • As of November 4, 2025, there were 44,194,408 shares of common stock outstanding.

Inbound Investments

  • Following the announcement of its intent to separate into two independent companies ("NewCo" and "RemainCo"), Teleflex received significant third-party interest and a number of inbound expressions of interest in acquiring NewCo.

Outbound Investments

  • In February 2025, Teleflex entered into an agreement to acquire substantially all of BIOTRONIK SE & Co. KG's Vascular Intervention business for an estimated cash payment of approximately €760 million (approximately $825.2 million).
  • This acquisition was completed in July 2025, expanding Teleflex's presence in the interventional cardiology and peripheral vascular markets.
  • The BIOTRONIK Vascular Intervention acquisition was funded by a $700 million delayed draw term loan and additional revolver borrowings, increasing total borrowings to $2,681,250.

Capital Expenditures

  • Over the last 12 months (as of November 2025), Teleflex reported capital expenditures of -$126.61 million.
  • Recent quarterly capital expenditure levels have generally remained in the $20 million to $40 million range.
  • The company expects to incur an additional $5 million to $7 million in capital expenditures primarily in 2026 and 2027 related to the VI Business Integration plan.

Better Bets vs. Teleflex (TFX)

Latest Trefis Analyses

Trade Ideas

Select ideas related to TFX.

Unique Key

Recent Active Movers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Peers to compare with:

Financials

TFXMDTBDXBSXEWSYKMedian
NameTeleflex MedtronicBecton D.Boston S.Edwards .Stryker  
Mkt Price103.7599.49175.8974.7375.87366.05101.62
Mkt Cap4.6127.550.2110.744.4140.080.5
Rev LTM3,19034,75821,92419,3505,88425,11620,637
Op Inc LTM5616,7193,1043,7201,6195,0593,412
FCF LTM2645,2062,6313,6288004,2833,130
FCF 3Y Avg3654,9172,7382,3786883,6352,558
CFO LTM3917,1133,3944,6261,0175,0444,010
CFO 3Y Avg4786,6263,4913,3059554,3323,398

Growth & Margins

TFXMDTBDXBSXEWSYKMedian
NameTeleflex MedtronicBecton D.Boston S.Edwards .Stryker  
Rev Chg LTM5.4%5.3%6.2%21.6%10.6%11.2%8.4%
Rev Chg 3Y Avg4.5%4.1%5.4%15.6%4.4%10.8%4.9%
Rev Chg Q19.4%6.6%1.6%20.3%14.7%11.4%13.0%
QoQ Delta Rev Chg LTM4.9%1.6%0.4%4.6%3.5%3.0%3.3%
Op Mgn LTM17.6%19.3%14.2%19.2%27.5%20.1%19.3%
Op Mgn 3Y Avg18.3%18.6%13.3%18.0%28.9%20.0%18.4%
QoQ Delta Op Mgn LTM-1.9%-0.1%0.5%0.9%-0.4%0.5%0.2%
CFO/Rev LTM12.3%20.5%15.5%23.9%17.3%20.1%18.7%
CFO/Rev 3Y Avg15.7%19.9%16.9%19.8%18.7%19.0%18.8%
FCF/Rev LTM8.3%15.0%12.0%18.7%13.6%17.1%14.3%
FCF/Rev 3Y Avg12.0%14.8%13.3%14.1%13.4%15.9%13.8%

Valuation

TFXMDTBDXBSXEWSYKMedian
NameTeleflex MedtronicBecton D.Boston S.Edwards .Stryker  
Mkt Cap4.6127.550.2110.744.4140.080.5
P/S1.43.72.35.77.55.64.6
P/EBIT-19.919.919.530.726.027.322.9
P/E-14.026.828.639.732.543.130.6
P/CFO11.717.914.823.943.627.820.9
Total Yield-6.5%6.6%5.9%2.5%3.1%3.2%3.2%
Dividend Yield0.7%2.8%2.4%0.0%0.0%0.9%0.8%
FCF Yield 3Y Avg4.5%4.4%4.3%2.0%1.5%2.8%3.6%
D/E0.60.20.40.10.00.10.2
Net D/E0.50.20.40.1-0.10.10.1

Returns

TFXMDTBDXBSXEWSYKMedian
NameTeleflex MedtronicBecton D.Boston S.Edwards .Stryker  
1M Rtn0.7%2.8%-15.1%-15.1%-10.1%0.6%-4.7%
3M Rtn-3.0%4.5%-8.4%-27.2%-12.1%1.3%-5.7%
6M Rtn-13.8%8.6%-9.3%-27.6%-3.1%-3.7%-6.5%
12M Rtn-37.3%10.6%-20.1%-29.6%-0.4%-4.1%-12.1%
3Y Rtn-56.9%30.3%-23.3%60.8%-1.8%43.2%14.2%
1M Excs Rtn2.0%2.1%-13.9%-19.0%-7.4%3.2%-2.7%
3M Excs Rtn-6.7%4.8%-7.7%-28.0%-11.1%0.1%-7.2%
6M Excs Rtn-19.8%4.1%-14.5%-33.9%-8.6%-8.5%-11.6%
12M Excs Rtn-50.6%-0.6%-33.4%-42.3%-12.9%-17.2%-25.3%
3Y Excs Rtn-124.2%-38.7%-91.9%-9.0%-68.8%-25.5%-53.8%

Financials

Segment Financials

Revenue by Segment
$ Mil20242023202220212020
Vascular access708684700658601
Interventional511445428382428
Surgical427393378317370
Anesthesia390389380302338
Original Equipment and Development Services (OEM)326273246220221
Interventional urology320323342290290
Other292285337367347
Total2,9742,7912,8102,5372,595


Price Behavior

Price Behavior
Market Price$103.75 
Market Cap ($ Bil)4.6 
First Trading Date02/18/1988 
Distance from 52W High-40.9% 
   50 Days200 Days
DMA Price$114.17$119.14
DMA Trenddowndown
Distance from DMA-9.1%-12.9%
 3M1YR
Volatility44.0%43.6%
Downside Capture94.90119.53
Upside Capture69.4356.81
Correlation (SPY)24.1%35.4%
TFX Betas & Captures as of 1/31/2026

 1M2M3M6M1Y3Y
Beta1.900.991.241.170.800.83
Up Beta4.372.511.341.480.640.73
Down Beta-0.600.120.691.330.850.84
Up Capture128%65%91%68%45%31%
Bmk +ve Days11223471142430
Stock +ve Days12213063119361
Down Capture551%189%194%130%118%104%
Bmk -ve Days9192754109321
Stock -ve Days8193061130385

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with TFX
TFX-37.8%43.3%-0.96-
Sector ETF (XLV)9.6%17.4%0.3740.4%
Equity (SPY)14.0%19.4%0.5535.5%
Gold (GLD)74.3%25.3%2.173.6%
Commodities (DBC)7.0%16.7%0.241.6%
Real Estate (VNQ)7.9%16.6%0.2830.6%
Bitcoin (BTCUSD)-29.8%44.9%-0.6515.7%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with TFX
TFX-23.1%33.3%-0.72-
Sector ETF (XLV)8.0%14.5%0.3748.4%
Equity (SPY)13.3%17.0%0.6243.7%
Gold (GLD)22.1%17.0%1.069.6%
Commodities (DBC)10.5%18.9%0.444.9%
Real Estate (VNQ)5.2%18.8%0.1843.5%
Bitcoin (BTCUSD)8.3%57.2%0.3716.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return		Annualized
Volatility		Sharpe
Ratio		Correlation
with TFX
TFX-2.0%31.5%0.01-
Sector ETF (XLV)11.2%16.5%0.5655.2%
Equity (SPY)15.6%17.9%0.7552.9%
Gold (GLD)15.3%15.6%0.825.8%
Commodities (DBC)8.1%17.6%0.3813.0%
Real Estate (VNQ)6.4%20.7%0.2748.0%
Bitcoin (BTCUSD)67.9%66.7%1.0714.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date1302026
Short Interest: Shares Quantity2.2 Mil
Short Interest: % Change Since 115202615.3%
Average Daily Volume1.0 Mil
Days-to-Cover Short Interest2.1 days
Basic Shares Quantity44.2 Mil
Short % of Basic Shares4.9%

Returns Analyses

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
11/6/2025-13.0%-10.4%-3.7%
7/31/20254.9%-1.6%11.1%
2/27/2025-21.7%-24.5%-21.3%
10/31/2024-14.5%-14.2%-17.9%
8/1/20246.8%2.0%10.4%
5/2/2024-6.1%-5.2%-1.0%
2/22/2024-5.3%-10.4%-10.4%
11/2/202311.6%6.9%21.6%
...
SUMMARY STATS   
# Positive659
# Negative151612
Median Positive4.9%2.0%8.8%
Median Negative-5.2%-6.6%-12.4%
Max Positive11.6%6.9%21.6%
Max Negative-21.7%-24.5%-35.6%

SEC Filings

Expand for More
Report DateFiling DateFiling
09/30/202511/06/202510-Q
06/30/202507/31/202510-Q
03/31/202505/01/202510-Q
12/31/202402/28/202510-K
09/30/202410/31/202410-Q
06/30/202408/02/202410-Q
03/31/202405/03/202410-Q
12/31/202302/23/202410-K
09/30/202311/03/202310-Q
06/30/202308/03/202310-Q
03/31/202305/04/202310-Q
12/31/202202/23/202310-K
09/30/202210/27/202210-Q
06/30/202207/28/202210-Q
03/31/202204/28/202210-Q
12/31/202103/01/202210-K

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value		Value of
Held Shares		Form
1Randle, Stuart A DirectBuy8072025115.861,000115,860874,395Form
2Krakauer, Andrew A DirectBuy8072025115.251,000115,250828,879Form
3Kelly, LiamChairman, President & CEODirectBuy8072025115.071,500172,6055,208,907Form
4Ryu, Jaewon DirectBuy8072025115.001,500172,500428,605Form
5Haggerty, Gretchen R DirectBuy8072025114.7550057,375723,499Form

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.